BSE filing, NSE: JENBURPH. Summary written from the filing by ALFA Finder's alert engine.
Jenburkt Pharmaceuticals Ltd: key numbers
- Share price
- ₹932.00
- Market cap
- ₹411.3 Cr
- Revenue (annual)
- ₹168.7 Cr
- Net profit (annual)
- ₹34.74 Cr
- P/E (TTM)
- 12.5×Sector 41.3×
- Promoter holding
- 46.62%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jenburkt Pharmaceuticals Ltd
All →Jenburkt Pharmaceuticals Q2 FY27 Results: Net Profit ₹10.2 Cr, Up 0.0% YoY
Jenburkt Pharmaceuticals posted Q2 revenue of Rs. 4,831.82 lakhs and PAT of Rs. 1,020.94 lakhs. Results were approved on 3 November 2026.
- Key figure
- Net profit ₹10.2 Cr · +0.0% YoY
Jenburkt Pharmaceuticals Board Meeting Date
Jenburkt Pharmaceuticals has intimated that its Board will meet on 3 Nov 2026 to consider Q2/H1-26 financial results. No decision has been taken yet.
Jenburkt Pharmaceuticals Capital Structure Change
Counter Cyclical Investments Private Limited acquired 326 shares of Jenburkt Pharmaceuticals Ltd in the open market, increasing its total shareholding from 4.99% to 5.01%.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals submitted a certificate under SEBI Regulation 74(5) regarding share dematerialization for the quarter ended September 30, 2026.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.
Jenburkt Pharmaceuticals Management Change
Mr. Vinay Bhatt, Senior Vice President- International Business, has resigned from Jenburkt Pharmaceuticals Limited effective September 18, 2026, due to personal reasons.
Other capital structure change announcements
All →Dr. Lal Pathlabs Capital Structure Change
Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.
- Value
- ₹49.50 Cr
- Execution
- Indicative completion by 31 March 2027, in tranches
Atul Capital Structure Change
Atul bought back 4,100 equity shares on 4 November 2026 for ₹2.09 Crore. Cumulative buyback utilisation stands at ₹10.82 Crore of ₹90 Crore earmarked.
- Value
- ₹2.09 Cr
Premier Explosives Capital Structure Change
Rajasthan Global Securities sold 26,53,831 shares of Premier Explosives Ltd in the open market and offer. The sale reduced the non-promoter entity's stake from 5.90% to 0.08%.
Ola Electric Mobility Capital Structure Change
Promoter and Director Bhavish Aggarwal acquired 9,81,99,966 partly paid-up equity shares of Ola Electric Mobility Ltd for ₹1,590.84 Crore. The acquisition was executed via a rights issue allotment.
- Value
- ₹159.1 Cr
Ennature Bio Pharma Capital Structure Change
Ennature Bio Pharma listed its equity shares on NSE and BSE on 4 November 2026. The company brings its API, biopolymer and nutraceutical businesses to public markets.
Identixweb Capital Structure Change
NAV Capital Emerging Star Fund, a non-promoter, bought 48,000 Identixweb shares in the open market on 2 Nov 2026, lifting its stake to 5.11%. No per-share price or total consideration is disclosed.